Sandoz Foundation to Divest CHF2.6B Novartis Stake

The Sandoz Family Foundation, a prominent Swiss institution and Novartis's second-largest shareholder, has announced plans to divest a substantial portion of its stake in the pharmaceutical giant. The foundation, through its holding company Emasan AG, will sell 26.5 million shares, representing approximately 1.2% of Novartis's total outstanding shares. This significant move comes as part of the foundation's broader strategy to diversify its investment portfolio.

The transaction, valued at approximately CHF2.6 billion, will be executed through an accelerated bookbuilding process. The shares are being offered at CHF98.25 each, representing a slight discount to Novartis's closing price of CHF100.72. The foundation currently holds a 4.1% stake in Novartis, making this sale a significant portion of their total holding. The transaction's structure as an accelerated bookbuilding process suggests a swift execution aimed at minimizing market impact.

The Sandoz Family Foundation's relationship with Novartis dates back to 1866 when the Sandoz family established the Sandoz chemical company in Basel. This historical connection was maintained through the 1996 merger between Ciba-Geigy and Sandoz, which formed Novartis. The foundation has since been a key shareholder in the pharmaceutical group, while also maintaining its focus on education, vocational training, and cultural initiatives in Switzerland through various programs, including the Fondation Edouard et Maurice Sandoz (FEMS).

The announcement of this significant share sale marks a strategic shift in the Sandoz Family Foundation's investment approach. While the foundation maintains its commitment to Swiss industrial heritage, the move reflects a modern portfolio management strategy focused on diversification. The transaction's structure and timing suggest careful consideration to minimize market disruption, while the slight discount in the offer price aims to ensure successful placement. This divestment may lead to increased free float in Novartis shares, potentially enhancing market liquidity while maintaining the company's strong Swiss roots.